Critical Path Institute’s (C-Path) Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) consortium today announced the addition of several key advisory members. The new members, recognized experts in their respective fields and patient advocacy organizations, will contribute their significant expertise to the consortium’s mission to accelerate drug development for Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder. Among the selected is the A1F Chair of the Board of Directors, Jon Hagstrom, a ZZ Alpha and double lung transplant recipient.
Joining the consortium are:
Alpha-1 Foundation
COPD Foundation
Global Liver Institute (GLI)
Jon Hagstrom, Board Member, Alpha-1 Foundation
Noel G. McElvaney, Royal College of Surgeons in Ireland
Marc Miravitlles, M.D., Pulmonologist at the Pneumology Department, University Hospital Vall d’Hebron / Vall d’Hebron Research Institute in Barcelona, Spain
Jeff Teckman, M.D., Pediatric Hepatologist at Saint Louis University
Alice Turner, MBChB, MRCP, PGCE, Ph.D., Professor of Respiratory Medicine, University of Birmingham, United Kingdom
Hugo E. Vargas, M.D., Professor of Medicine, Mayo Clinic
Andrew A. Wilson, M.D., Professor of Medicine and Director of The Alpha-1 Center, Boston University and Boston Medical Center
“We’re truly excited about the new members joining our consortium,” said Amanda Klein, Pharm.D., Executive Director of the CPA-1 consortium. “With their deep expertise and fresh perspectives, they will be key in helping us develop new treatments more efficiently and effectively. This is a major step forward in our fight against AATD.”
AATD affects the liver and lungs, leading to serious health conditions such as liver disease and emphysema. The disorder, impacting an estimated 100,000 people in the U.S. alone, often manifests as chronic obstructive pulmonary disease around 40 years of age. Infants with AATD also face significant risks, as approximately 10% exhibit liver function abnormalities that may eventually require transplantation.
Read the full press release, here.
Great to see some of our best (and busiest) expert alpha docs and others going above and beyond. Their commitment warms the heart of every alpha and gives them hope!
Congratulations and thank you to all who participate in this important Venture.